All News

Found 79 articles

• UroGen Pharma Reports First Quarter 2021 Financial Results and Recent Corporate Developments

  5/13/2021

  UroGen Pharma today announced financial results for the first quarter ended March 31, 2021 and provided an overview of the Company’s recent developments.

• Blue Water Acquisition Corporation Announces Merger Agreement with Clarus Therapeutics, Forming A Publicly Listed Company To Address Unmet Needs Of Men And Women Through Development Of Androgen And Metabolic Therapies

  4/27/2021

  Existing Clarus investors, led by H. I. G. Capital, will invest an additional $25 million in support of the company Transaction will accelerate commercialization of JATENZO®, the market-leading oral testosterone replacement therapy, and fund expansion of the company's pipeline of androgen and metabolic therapies for men and women, including orphan indications Clarus Therapeutics shareholders and Blue Water Acquisition Corp. shareholders will hold shares in Clarus Therapeutics

• One Year Since FDA Validation of South Carolina’s First COVID-19 Testing Laboratory

  3/29/2021

  Diversified Medical Healthcare (DMH), a holding company with four subsidiary healthcare companies, Premier Medical Laboratory Services (PMLS), CPT Medical, OnGen, and Vessel Medical, has provided leading-edge solutions to combat COVID-19 nationally, addressing supply chain gaps and infrastructure restrictions caused by the virus.

• Blue Water Vaccines Announces Development of Vaccine Candidates to Address G4 EA H1N1 Swine Influenza Virus and Streptococcus Pneumoniae

  10/29/2020

  Blue Water Vaccines, Inc., announced today that the Company is accelerating the development of a new vaccine candidate to combat the potential pandemic influenza strain, G4 EA H1N1, which was identified by scientists in China in the summer of 2020

• Blue Cross Blue Shield of Massachusetts Urges: Protect Yourself and Your Community By Getting a Flu Shot

  10/5/2020

    Blue Cross Blue Shield of Massachusetts  (Blue Cross) is supporting state and national public health experts in encouraging flu vaccinations. A severe flu outbreak this winter, coupled with a resurgence of the coronavirus, would pose a serious threat to individual and public health, as well as the health care system. 

• Blue Water Vaccines Licenses Patent Rights for Streptococcus Pneumoniae Vaccine Development from St. Jude Children's Research Hospital

  2/10/2020

  Blue Water Vaccines Inc., a biopharmaceutical company focused on creating transformative vaccines solving global health challenges, has entered into an exclusive worldwide license agreement for the development of a Streptococcus Pneumoniae vaccine with St. Jude Children's Research Hospital ("St. Jude")

• Blue Water Vaccines, Developing Universal Flu Vaccine, to Partner With Ology Bioservices Inc.

  8/7/2019

  CINCINNATI, August 7, 2019 - Blue Water Vaccines, a Cincinnati-based biotechnology startup, has signed an agreement with Ology Bioservices, Inc.

• Blue Water Vaccines, Developing Universal Flu Vaccine, Completes $7m Financing Following Successful Preclinical Study

  7/9/2019

  Blue Water Vaccines, a company developing a universal flu vaccine based on technology developed at the University of Oxford, has closed a $7 million seed capital round led by CincyTech.

• Blue Water Vaccines Announces Transaction for Universal Influenza Vaccine with Oxford University

  1/10/2019

  Blue Water Vaccines, Inc., a privately held company, announced today that the company has entered into an option agreement with the University of Oxford in the United Kingdom providing Blue Water Vaccines the option to exclusively license a novel and potentially revolutionary universal influenza vaccine.

• Talking Rain® Beverage Co. Strengthens Corporate Social Responsibility Commitments in October

  10/30/2018

  Talking Rain® Beverage Company, the makers of zero sugar Sparkling Ice®, is proud to share today a range of corporate social responsibly initiatives that have little to do with the company's success, and everything to do with its heart.

• NanoBio Announces Corporate Name Change to BlueWillow Biologics and Closes $10M Series A Financing

  5/7/2018

  Move Reflects Focus on Advancing Several Intranasal Vaccines to Human Studies

• Meet America's Top 10 Veterinary Professionals And Vote For Your Favorites!

  5/3/2018

  American Humane is pleased to announce that voting is now open in the fifth annual American Humane Hero Veterinarian and Hero Veterinary Nurse Award.

• Henry Schein, Inc. Partnership With The Professional Baseball Athletic Trainers Society (PBATS) Hosts 21 "Home Run For Health" Events In 2014

  11/7/2014

• Inovio Pharmaceuticals' DNA Vaccine for Foot-and-Mouth Disease Generates Protective Neutralizing Antibodies in Second Large-Animal Study

  6/30/2011

• Inovio Pharmaceuticals (Formerly Known as Inovio Biomedical Corporation)' Foot-and-Mouth Disease DNA Vaccine Introduces Critical Advantages in Fight Against Most Serious Farm Animal Disease

  3/2/2011

• First Self-Replicating, Synthetic Bacterial Cell Constructed by J. Craig Venter Institute Researchers

  5/21/2010

• GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. Following FDA Approval, Agreement will Broaden Access to Cholesterol-Reducing Medicine

  11/27/2007

• Skyepharma PLC Responds To Allegations Made By North Atlantic Value Group

  3/3/2006

• Regence BlueCross BlueShield Of Oregon Announces Coverage Of FluMist In Response To The Shortage Of Injectable Flu Vaccine

  10/27/2004